Previous 10 | Next 10 |
2019 has not been kind to United Therapeutic's ( UTHR ) share price so far; the price has collapsed from a high of $125, to $78.54 at the time of writing. Source: TradingView The slump is mainly due to the expiry, or impending expiry of its exclusivity patents for key drug Adcirca, as w...
MannKind ( MNKD ) saw a record week in scripts to close out Q3. For the week ending September 27th, Afrezza scripts came in at 881 with retail sales of $1.412 million. Both of these are numbers much higher than we have recently seen, and there seems to have been quite a bit of discussion as to...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Sept. 11, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Trevyent® (treprostinil) f...
MannKind ( MNKD ) presented today at the HC Wainwright Global Investment Conference . One of the big differences between this presentation and similar ones over the past two years, to be blunt, is that the company is not looking for money at this conference. In the past, MannKind has essentia...
In the Fall of 2018, United Therapeutics ( UTHR ) and MannKind ( MNKD ) announced a deal for a "secret molecule" for PAH which would have MannKind doing some concept formulation work. Upon completion of that formulation work, United Therapeutics would make a decision on whether or not to move ...
It has been a few weeks since I covered scripts, cash, and the usual metrics in a MannKind (MNKD) article. Instead, I took a step back to conduct "vision" interviews with the shareholder activist movement known as HFM and with MannKind's management. The purpose of the "vision" articles was to ...
NEW YORK, Aug. 19, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a Master Services Agreement (“MSA”) with Lung Biotechnology PBC, a subsidiary of United Therapeutics Corporation (NASDAQ:UTHR), to produce recombinant human col...
MannKind ( MNKD ) reported its Q2 earnings after the bell on Wednesday, August 7th. For the quarter, it reported a net loss of $12.4 million on revenues of $15 million, which included the recognition of $8.9 million from a milestone payment. Overall, there were several improvements made in...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Aug. 6, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt , Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the comp...
MannKind's ( MNKD ) investors have had an interesting week. The drama from the activist campaign has seen a bit of a lull, but that does not mean that there was nothing happening. This week the company saw executives make some small buys of the company's stock, the announcement of a date for t...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...